Market Cap | 11.47B | P/E | - | EPS this Y | -3.90% | Ern Qtrly Grth | -80.80% |
Income | -1.29B | Forward P/E | 4.11 | EPS next Y | 1.20% | 50D Avg Chg | 9.00% |
Sales | 15.14B | PEG | 1.85 | EPS past 5Y | -7.31% | 200D Avg Chg | 16.00% |
Dividend | N/A | Price/Book | 1.31 | EPS next 5Y | 2.00% | 52W High Chg | -10.00% |
Recommedations | 2.90 | Quick Ratio | 0.52 | Shares Outstanding | 1.11B | 52W Low Chg | 52.00% |
Insider Own | 1.88% | ROA | 3.88% | Shares Float | 1.10B | Beta | 1.25 |
Inst Own | 49.68% | ROE | -12.45% | Shares Shorted/Prior | 23.98M/30.81M | Price | 10.33 |
Gross Margin | 47.90% | Profit Margin | -8.53% | Avg. Volume | 9,977,924 | Target Price | 9.60 |
Oper. Margin | 18.89% | Earnings Date | - | Volume | 2,932,469 | Change | -0.53% |
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Piper Sandler | Underweight | Nov 23, 22 |
JP Morgan | Underweight | Nov 14, 22 |
BMO Capital | Market Perform | Nov 7, 22 |
B of A Securities | Buy | Aug 5, 22 |
Goldman Sachs | Neutral | Aug 2, 22 |
UBS | Neutral | Jun 14, 22 |
B of A Securities | Neutral | May 17, 22 |
Goldman Sachs | Neutral | May 12, 22 |
Piper Sandler | Underweight | May 4, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Kalif Eliyahu Sharon | EVP, Chief Financial.. EVP, Chief Financial Officer | Aug 22 | Sell | 10.0666 | 55,500 | 558,696 | 9,376 | 08/24/22 |
Stark David Matthew | Exec. VP Chief Legal.. Exec. VP Chief Legal Officer | Jul 28 | Sell | 9.0365 | 58,163 | 525,590 | 2,974 | 07/29/22 |
Fridriksdottir Hafrun | Executive VP, Global.. Executive VP, Global R&D | May 17 | Sell | 8.2159 | 130,000 | 1,068,067 | 1,387 | 05/19/22 |
Drape Eric | Executive VP Global.. Executive VP Global Operations | Mar 04 | Sell | 7.44 | 34,792 | 258,852 | 78,072 | 03/08/22 |
Dethlefs Sven | EVP, North America C.. EVP, North America Commercial | Mar 04 | Sell | 7.42 | 10,897 | 80,856 | 165,381 | 03/08/22 |
Daniell Richard | Exec. VP, European C.. Exec. VP, European Commercial | Mar 04 | Sell | 7.44 | 58,952 | 438,603 | 43,182 | 03/08/22 |
Stark David Matthew | Exec. VP Chief Legal.. Exec. VP Chief Legal Officer | Feb 28 | Sell | 8.14 | 6,452 | 52,519 | 21,380 | 03/02/22 |
Shani Eli | EVP,Global Marketing.. EVP,Global Marketing&Portfolio | Feb 28 | Sell | 8.14 | 5,311 | 43,232 | 9,091 | 03/02/22 |
Fridriksdottir Hafrun | Executive VP, Global.. Executive VP, Global R&D | Feb 28 | Sell | 8.14 | 7,590 | 61,783 | 65,509 | 03/02/22 |
Drape Eric | Executive VP Global.. Executive VP Global Operations | Feb 28 | Sell | 8.14 | 9,797 | 79,748 | 45,830 | 03/02/22 |
Dethlefs Sven | EVP, North America C.. EVP, North America Commercial | Feb 28 | Sell | 8.14 | 4,862 | 39,577 | 99,457 | 03/02/22 |
Daniell Richard | Exec. VP, European C.. Exec. VP, European Commercial | Feb 28 | Sell | 8.14 | 20,598 | 167,668 | 20,280 | 03/02/22 |
Stark David Matthew | Exec. VP Chief Legal.. Exec. VP Chief Legal Officer | Feb 08 | Sell | 9.06 | 6,110 | 55,357 | 9,402 | 02/10/22 |
Stark David Matthew | Exec. VP Chief Legal.. Exec. VP Chief Legal Officer | May 13 | Sell | 10.22 | 37,884 | 387,174 | 2,974 | 05/13/21 |
Drape Eric | Executive VP Global.. Executive VP Global Operations | May 13 | Sell | 10.22 | 19,804 | 202,397 | 73,128 | 05/13/21 |
Nazzi Gianfranco | EVP, International M.. EVP, International Markets | Mar 08 | Sell | 10.58 | 12,935 | 136,852 | 03/08/21 | |
Drape Eric | Executive VP Global.. Executive VP Global Operations | Mar 08 | Sell | 10.58 | 6,183 | 65,416 | 55,048 | 03/08/21 |
Dethlefs Sven | EVP Global Marketing.. EVP Global Marketing&Portfolio | Mar 08 | Sell | 10.57 | 6,012 | 63,547 | 77,976 | 03/08/21 |
Nazzi Gianfranco | EVP, International M.. EVP, International Markets | Mar 04 | Sell | 10.88 | 1,400 | 15,232 | 03/04/21 | |
Fridriksdottir Hafrun | Executive VP, Global.. Executive VP, Global R&D | Feb 17 | Sell | 11.12 | 2,098 | 23,330 | 103,294 | 02/17/21 |
O'Grady Brendan P. | EVP, North America C.. EVP, North America Commercial | Feb 11 | Sell | 12.69 | 20,694 | 262,607 | 78,146 | 02/11/21 |
Dethlefs Sven | EVP Global Marketing.. EVP Global Marketing&Portfolio | Feb 11 | Sell | 12.69 | 29,657 | 376,347 | 59,404 | 02/11/21 |
Daniell Richard | Exec. VP, European C.. Exec. VP, European Commercial | Sep 10 | Sell | 8.98 | 333 | 2,990 | 10,765 | 09/10/20 |